DRNA News and Press, Dicerna Pharmaceuticals Inc. From 08/06/21

Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...

Gainers: SCWorx (NASDAQ:WORX) +28%, Aurinia Pharmaceuticals (NASDAQ:AUPH) +21%, BeyondSpring (NASDAQ:BYSI) +13%, Intersect ENT (NASDAQ:XENT) +12%, Caribou Biosciences (NASDAQ:CRBU) +11%. Losers: Dicerna Pharmaceuticals (NASDAQ:DRNA) -35%, iCAD (NAS...

Spectrum Pharmaceuticals SPPI -35% after FDA declines to approve ROLONTIS Dicerna Pharmaceuticals DRNA -28% slide despite pivotal nedosiran study hitting primary endpoint Zynga ZNGA -16% on Q2 earnings release Chembio Diagnostics CEMI -13% on Q2 earning...

Dicerna Pharmaceuticals (NASDAQ:DRNA) shares have slid more than 30% post-market despite meeting the primary endpoint in a pivotaql  trial of nedosiran in patients with primary hyperoxaluria (PH). The likely reason for the decline is that urinary oxalate ((Uox)) excre...

– Nedosiran Achieved Primary Endpoint, Demonstrating Statistically and Clinically Significant Sustained Reduction in Urinary Oxalate Excretion; Key Secondary Endpoint Also Achieved; Robust Efficacy Seen in PH1 Participants – – Nedosiran Was Generally Well ...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its second quarter 2021 financial results be...

– Novel ALDH2- Targeting GalXC™ RNAi Candidate Designed to Address a Highly Prevalent and Undertreated Disorder 1 – – Dicerna Expects to Initiate Phase 1 Clinical Trial of DCR-AUD in the Third Quarter of 2021 – Dicerna...

alexsl/iStock via Getty Images Having closed at the highest level since early 2014 on Tuesday, Dicerna Pharmaceuticals (DRNA) dropped ~3.8% today after the company announced interim data for belcesiran in Alpha-1 antitrypsin deficiency-associated liver disease ((AATLD)). D...

– Interim Results From Phase 1 Study Enabled Initiation and First Patient Dosing in Phase 2 ESTRELLA Study, Which Is Currently Underway – Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading develo...

Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...